{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:09:01Z","timestamp":1789186141695,"version":"build-2803163510"},"reference-count":58,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,12]]},"DOI":"10.1248\/bpb.b26-00374","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:11:28Z","timestamp":1789164688000},"page":"1500-1510","source":"Crossref","is-referenced-by-count":0,"title":["Highly-Efficient Cellular Uptake and Membrane Permeability of Cell-Penetrating Peptides &lt;i&gt;via&lt;\/i&gt; Introduction of Homoarginine Residues"],"prefix":"10.1248","volume":"49","author":[{"given":"Ryunosuke","family":"Taniyama","sequence":"first","affiliation":[{"name":"Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, 1\u20131 Gakuen-cho, Naka-ku, Sakai 599\u20138531, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, 1\u20131 Gakuen-cho, Naka-ku, Sakai 599\u20138531, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Hattori","sequence":"additional","affiliation":[{"name":"Research Center for Boron Neutron Capture Therapy (BNCT), Osaka Metropolitan University, 1\u20132 Gakuen-cho, Naka-ku, Sakai 599\u20138570, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Michigami","sequence":"additional","affiliation":[{"name":"Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, 1\u20131 Gakuen-cho, Naka-ku, Sakai 599\u20138531, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentarou","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, 1\u20131 Gakuen-cho, Naka-ku, Sakai 599\u20138531, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Takatani-Nakase","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunori","family":"Kirihata","sequence":"additional","affiliation":[{"name":"Research Center for Boron Neutron Capture Therapy (BNCT), Osaka Metropolitan University, 1\u20132 Gakuen-cho, Naka-ku, Sakai 599\u20138570, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Fujii","sequence":"additional","affiliation":[{"name":"Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, 1\u20131 Gakuen-cho, Naka-ku, Sakai 599\u20138531, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuhiko","family":"Nakase","sequence":"additional","affiliation":[{"name":"Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, 1\u20131 Gakuen-cho, Naka-ku, Sakai 599\u20138531, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Gautam R, Singh D. Endosomal entrapment: the silent failure point of cancer nanotherapeutics and how pharmaceutical design can overcome it. <i>Asia Pac. J. Clin. Oncol.,<\/i> <b>70114<\/b> <b>(<\/b>2026).","DOI":"10.1111\/ajco.70114"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>121<\/b>, e2307800120 (2024).","DOI":"10.1073\/pnas.2307800120"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nakase I, Kobayashi S, Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. <i>Biopolymers<\/i>, <b>94<\/b>, 763\u2013770 (2010).","DOI":"10.1002\/bip.21487"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lu RM, Chiang HL, Yuan JP, Wang HH, Chen CY, Panda SS, Liang KH, Peng HP, Ko SH, Hsu HJ, Kumari M, Su YJ, Tse YT, Chou NL, Wu HC. Technological advancements in antibody-based therapeutics for treatment of diseases. <i>J. Biomed. Sci.<\/i>, <b>32<\/b>, 98 (2025).","DOI":"10.1186\/s12929-025-01190-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Li M, Zhao X, Yu C, Wang L. Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy. <i>Pharm. Res.<\/i>, <b>41<\/b>, 419\u2013440 (2024).","DOI":"10.1007\/s11095-023-03649-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Flynn P, Suryaprakash S, Grossman D, Panier V, Wu J. The antibody-drug conjugate landscape. <i>Nat. Rev. Drug Discov.<\/i>, <b>23<\/b>, 577\u2013578 (2024).","DOI":"10.1038\/d41573-024-00064-w"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody-drug conjugates. <i>Biomedicines<\/i>, <b>11<\/b>, 3080 (2023).","DOI":"10.3390\/biomedicines11113080"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Bhakta-Yadav MS, Brown TL. Important aspects of siRNA design for optimal efficacy in vitro and in vivo. <i>Int. J. Cell Biol.<\/i>, <b>2025<\/b>, 6663816 (2025).","DOI":"10.1155\/ijcb\/6663816"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Shevelev A, Pozdniakova N, Generalov E, Tarasova O. siRNA therapeutics for the treatment of hereditary diseases and other conditions: a review. <i>Int. J. Mol. Sci.<\/i>, <b>26<\/b>, 8651 (2025).","DOI":"10.3390\/ijms26178651"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Futaki S, Nakase I. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization. <i>Acc. Chem. Res.<\/i>, <b>50<\/b>, 2449\u20132456 (2017).","DOI":"10.1021\/acs.accounts.7b00221"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Viv\u00e8s E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. <i>J. Biol. Chem.<\/i>, <b>272<\/b>, 16010\u201316017 (1997).","DOI":"10.1074\/jbc.272.25.16010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. <i>J. Biol. Chem.<\/i>, <b>269<\/b>, 10444\u201310450 (1994).","DOI":"10.1016\/S0021-9258(17)34080-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. <i>Nat. Med.<\/i>, <b>6<\/b>, 1253\u20131257 (2000).","DOI":"10.1038\/81359"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. <i>J. Biol. Chem.<\/i>, <b>276<\/b>, 5836\u20135840 (2001).","DOI":"10.1074\/jbc.M007540200"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, Takehashi M, Tanaka S, Ueda K, Simpson JC, Jones AT, Sugiura Y, Futaki S. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. <i>Mol. Ther.<\/i>, <b>10<\/b>, 1011\u20131022 (2004).","DOI":"10.1016\/j.ymthe.2004.08.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nakase I, Osaki K, Tanaka G, Utani A, Futaki S. Molecular interplays involved in the cellular uptake of octaarginine on cell surfaces and the importance of syndecan-4 cytoplasmic V domain for the activation of protein kinase C\u03b1. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>446<\/b>, 857\u2013862 (2014).","DOI":"10.1016\/j.bbrc.2014.03.018"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nakase I, Tadokoro A, Kawabata N, Takeuchi T, Katoh H, Hiramoto K, Negishi M, Nomizu M, Sugiura Y, Futaki S. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. <i>Biochemistry<\/i>, <b>46<\/b>, 492\u2013501 (2007).","DOI":"10.1021\/bi0612824"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tanaka G, Nakase I, Fukuda Y, Masuda R, Oishi S, Shimura K, Kawaguchi Y, Takatani-Nakase T, Langel U, Gr\u00e4slund A, Okawa K, Matsuoka M, Fujii N, Hatanaka Y, Futaki S. CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV. <i>Chem. Biol.<\/i>, <b>19<\/b>, 1437\u20131446 (2012).","DOI":"10.1016\/j.chembiol.2012.09.011"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kosuge M, Takeuchi T, Nakase I, Jones AT, Futaki S. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. <i>Bioconjug. Chem.<\/i>, <b>19<\/b>, 656\u2013664 (2008).","DOI":"10.1021\/bc700289w"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kawaguchi Y, Takeuchi T, Kuwata K, Chiba J, Hatanaka Y, Nakase I, Futaki S. Syndecan-4 is a receptor for clathrin-mediated endocytosis of arginine-rich cell-penetrating peptides. <i>Bioconjug. Chem.<\/i>, <b>27<\/b>, 1119\u20131130 (2016).","DOI":"10.1021\/acs.bioconjchem.6b00082"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Zhang C, Zhang A, Yu H, Ma Y, Zhang Y, Geng H, Wu D, Zuo L, Hao C, Lin X, Qi Y, Zhang H, Shi N. Bio-interfacial design of CPP- and TPP-functionalized nanocarriers for barrier-limited delivery: Mechanisms, design rules, and applications. <i>Colloids Surf. B Biointerfaces<\/i>, <b>265<\/b>, 115730 (2026).","DOI":"10.1016\/j.colsurfb.2026.115730"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Geng J, Xia X, Teng L, Wang L, Chen L, Guo X, Belingon B, Li J, Feng X, Li X, Shang W, Wan Y, Wang H. Emerging landscape of cell-penetrating peptide-mediated nucleic acid delivery and their utility in imaging, gene-editing, and RNA-sequencing. <i>J. Control. Release<\/i>, <b>341<\/b>, 166\u2013183 (2022).","DOI":"10.1016\/j.jconrel.2021.11.032"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kim EJ, Lee Y, Ryu J, Kim H, Park J, Lee J. Cell-penetrating peptides for therapeutic applications: emerging design strategies and future directions. <i>Org. Biomol. Chem.<\/i>, <b>24<\/b>, 1938\u20131964 (2026).","DOI":"10.1039\/D6OB00146G"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Datta N. A review on the cell-penetrating peptides. <i>Cell Therapy &amp; Engineering Connect<\/i>, <b>1<\/b>, 2025.0005 (2025).","DOI":"10.69709\/CellEngC.2025.145023"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Moreno-Vargas LM, Prada-Gracia D. Cancer-targeting applications of cell-penetrating peptides. <i>Int. J. Mol. Sci.<\/i>, <b>26<\/b>, 2 (2025).","DOI":"10.3390\/ijms26010002"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Anjous R, Kavyashree P, Saha A. Strategies to improve intracellular delivery of arginine-rich cell-penetrating peptides. <i>J. Mater. Chem. B<\/i>, <b>14<\/b>, 3596\u20133619 (2026).","DOI":"10.1039\/D5TB02935J"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Pujals S, Miyamae H, Afonin S, Murayama T, Hirose H, Nakase I, Taniuchi K, Umeda M, Sakamoto K, Ulrich AS, Futaki S. Curvature engineering: positive membrane curvature induced by epsin N-terminal peptide boosts internalization of octaarginine. <i>ACS Chem. Biol.<\/i>, <b>8<\/b>, 1894\u20131899 (2013).","DOI":"10.1021\/cb4002987"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Maniti O, Piao HR, Ayala-Sanmartin J. Basic cell penetrating peptides induce plasma membrane positive curvature, lipid domain separation and protein redistribution. <i>Int. J. Biochem. Cell Biol.<\/i>, <b>50<\/b>, 73\u201381 (2014).","DOI":"10.1016\/j.biocel.2014.02.017"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Castro LM, Paiva L, Lobo I, Neves AR, Albuquerque T, Sousa \u00c2, Costa D. Modeling 3D glioblastoma: a review of spheroid culture techniques and standardization challenges. <i>Methods<\/i>, <b>253<\/b>, 129\u2013141 (2026).","DOI":"10.1016\/j.ymeth.2026.05.013"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Palermo N, Pant\u00f2 G, Catalfamo A, Filippone A, Esposito E. Impact of spheroid use for identifying hepatocellular carcinoma features: involvement of kinase-mediated molecular pathways. <i>Front. Biosci. (Landmark Ed.)<\/i>, <b>31<\/b>, 45980 (2026).","DOI":"10.31083\/FBL45980"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Soloway AH, Hatanaka H, Davis MA. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. <i>J. Med. Chem.<\/i>, <b>10<\/b>, 714\u2013717 (1967).","DOI":"10.1021\/jm00316a042"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Hatanaka H. A revised boron-neutron capture therapy for malignant brain tumors. II. Interim clinical result with the patients excluding previous treatments. <i>J. Neurol.<\/i>, <b>209<\/b>, 81\u201394 (1975).","DOI":"10.1007\/BF00314601"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kobayashi T, Kanda K, Yoshino K. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking <sup>10<\/sup>B-compound. <i>Lancet<\/i>, <b>334<\/b>, 388\u2013389 (1989).","DOI":"10.1016\/S0140-6736(89)90567-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Barth RF, Vicente MG, Harling OK, Kiger WS 3rd, Riley KJ, Binns PJ, Wagner FM, Suzuki M, Aihara T, Kato I, Kawabata S. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. <i>Radiat. Oncol.<\/i>, <b>7<\/b>, 146 (2012).","DOI":"10.1186\/1748-717X-7-146"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Moss RL. Critical review, with an optimistic outlook, on boron neutron capture therapy (BNCT). <i>Appl. Radiat. Isot.<\/i>, <b>88<\/b>, 2\u201311 (2014).","DOI":"10.1016\/j.apradiso.2013.11.109"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Suzuki M. Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era. <i>Int. J. Clin. Oncol.<\/i>, <b>25<\/b>, 43\u201350 (2020).","DOI":"10.1007\/s10147-019-01480-4"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Hattori Y, Andoh T, Kawabata S, Hu N, Michiue H, Nakamura H, Nomoto T, Suzuki M, Takata T, Tanaka H, Watanabe T, Ono K. Proposal of recommended experimental protocols for <i>in vitro<\/i> and <i>in vivo<\/i> evaluation methods of boron agents for neutron capture therapy. <i>J. Radiat. Res.<\/i>, <b>64<\/b>, 859\u2013869 (2023).","DOI":"10.1093\/jrr\/rrad064"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Barth RF, Gupta N, Kawabata S. Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. <i>Cancer Commun.<\/i>, <b>44<\/b>, 893\u2013909 (2024).","DOI":"10.1002\/cac2.12582"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Nakashima H. The new generation of particle therapy focused on boron element (boron neutron capture therapy; BNCT) -The world\u2019s first approved BNCT drug. <i>Yakugaku Zasshi<\/i>, <b>142<\/b>, 155\u2013164 (2022).","DOI":"10.1248\/yakushi.21-00173-4"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Sato M, Hirose K, Takeno S, Aihara T, Nihei K, Takai Y, Hayashi T, Bando K, Kimura H, Tsurumi K, Ono K. Safety of boron neutron capture therapy with borofalan(<sup>10<\/sup>B) and its efficacy on recurrent head and neck cancer: real-world outcomes from nationwide post-marketing surveillance. <i>Cancers<\/i>, <b>16<\/b>, 869 (2024).","DOI":"10.3390\/cancers16050869"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Nakase I, Aoki A, Sakai Y, Hirase S, Ishimura M, Takatani-Nakase T, Hattori Y, Kirihata M. Antibody-based receptor targeting using an Fc-binding peptide-dodecaborate conjugate and macropinocytosis induction for boron neutron capture therapy. <i>ACS Omega<\/i>, <b>5<\/b>, 22731\u201322738 (2020).","DOI":"10.1021\/acsomega.0c01377"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Yamashita H, Oba M, Misawa T, Tanaka M, Hattori T, Naito M, Kurihara M, Demizu Y. A helix-stabilized cell-penetrating peptide as an intracellular delivery tool. <i>Chembiochem<\/i>, <b>17<\/b>, 137\u2013140 (2016).","DOI":"10.1002\/cbic.201500468"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kato T, Yamashita H, Misawa T, Nishida K, Kurihara M, Tanaka M, Demizu Y, Oba M. Plasmid DNA delivery by arginine-rich cell-penetrating peptides containing unnatural amino acids. <i>Bioorg. Med. Chem.<\/i>, <b>24<\/b>, 2681\u20132687 (2016).","DOI":"10.1016\/j.bmc.2016.04.031"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Yamashita H, Kato T, Oba M, Misawa T, Hattori T, Ohoka N, Tanaka M, Naito M, Kurihara M, Demizu Y. Development of a cell-penetrating peptide that exhibits responsive changes in its secondary structure in the cellular environment. <i>Sci. Rep.<\/i>, <b>6<\/b>, 33003 (2016).","DOI":"10.1038\/srep33003"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Yokoo H, Misawa T, Demizu Y. <i>De novo<\/i> design of cell-penetrating foldamers. <i>Chem. Rec.<\/i>, <b>20<\/b>, 912\u2013921 (2020).","DOI":"10.1002\/tcr.202000047"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Oba M. Development of cell-penetrating peptides and their application to DDS. <i>Chem. Pharm. Bull.<\/i>, <b>73<\/b>, 574\u2013580 (2025).","DOI":"10.1248\/cpb.c25-00272"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Inokuma A, Yokoo H, Demizu Y. Structure-function relationships of amphipathic (Arg-Arg-Aib)<sub>n<\/sub> peptides: impact of chirality and chain length on membrane permeability and nucleic acid delivery. <i>Chem. Pharm. Bull.<\/i>, <b>74<\/b>, 253\u2013259 (2026).","DOI":"10.1248\/cpb.c26-00014"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Salehi D, Mozaffari S, Zoghebi K, Lohan S, Mandal D, Tiwari RK, Parang K. Amphiphilic cell-penetrating peptides containing natural and unnatural amino acids as drug delivery agents. <i>Cells<\/i>, <b>11<\/b>, 1156 (2022).","DOI":"10.3390\/cells11071156"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Takeuchi K, Misaki I, Tokunaga Y, Fujisaki M, Kamoshida H, Takizawa T, Hanzawa H, Shimada I. Conformational plasticity of cyclic ras-inhibitor peptides defines cell permeabilization activity. <i>Angew. Chem. Int. Ed.<\/i>, <b>60<\/b>, 6567\u20136572 (2021).","DOI":"10.1002\/anie.202016647"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>104<\/b>, 20805\u201320810 (2007).","DOI":"10.1073\/pnas.0706574105"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Herce HD, Garcia AE, Cardoso MC. Fundamental molecular mechanism for the cellular uptake of guanidinium-rich molecules. <i>J. Am. Chem. Soc.<\/i>, <b>136<\/b>, 17459\u201317467 (2014).","DOI":"10.1021\/ja507790z"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Gimenez-Dejoz J, Numata K. Molecular dynamics study of the internalization of cell-penetrating peptides containing unnatural amino acids across membranes. <i>Nanoscale Adv.<\/i>, <b>4<\/b>, 397\u2013407 (2022).","DOI":"10.1039\/D1NA00674F"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Iv\u00e1nczi M, Balogh B, Kis L, M\u00e1ndity I. Molecular dynamics simulations of drug-conjugated cell-penetrating peptides. <i>Pharmaceuticals<\/i>, <b>16<\/b>, 1251 (2023).","DOI":"10.3390\/ph16091251"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Sakamoto K, Akishiba M, Iwata T, Murata K, Mizuno S, Kawano K, Imanishi M, Sugiyama F, Futaki S. Optimizing charge switching in membrane lytic peptides for endosomal release of biomacromolecules. <i>Angew. Chem. Int. Ed.<\/i>, <b>59<\/b>, 19990\u201319998 (2020).","DOI":"10.1002\/anie.202005887"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Akishiba M, Takeuchi T, Kawaguchi Y, Sakamoto K, Yu HH, Nakase I, Takatani-Nakase T, Madani F, Gr\u00e4slund A, Futaki S. Cytosolic antibody delivery by lipid-sensitive endosomolytic peptide. <i>Nat. Chem.<\/i>, <b>9<\/b>, 751\u2013761 (2017).","DOI":"10.1038\/nchem.2779"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Sakamoto K, Akishiba M, Iwata T, Arafiles JVV, Imanishi M, Futaki S. Use of homoarginine to obtain attenuated cationic membrane lytic peptides. <i>Bioorg. Med. Chem. Lett.<\/i>, <b>40<\/b>, 127925 (2021).","DOI":"10.1016\/j.bmcl.2021.127925"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Enninful GN, Kuppusamy R, Tiburu E, Kumar N, Willcox MDP. Assessing the effect of substitution of arginine with homoarginine in two antimicrobial peptides. <i>Int. J. Pept. Res. Ther.<\/i>, <b>32<\/b>, 24 (2026).","DOI":"10.1007\/s10989-026-10804-8"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Liu D, Zhang M, Li M. Direct cytosolic uptake of cell penetrating peptides with shortened sidechains. <i>Chembiochem<\/i>, <b>26<\/b>, e202500391 (2025).","DOI":"10.1002\/cbic.202500391"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00374\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:26:45Z","timestamp":1789183605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00374\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00374","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"article-number":"b26-00374"}}